Cabaletta Bio Soars 13.26% on Bullish Analyst Outlook

On May 16, 2025, Cabaletta Bio's stock surged by 13.26% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Guggenheim analyst Yatin Suneja has maintained a 'Buy' rating on Cabaletta Bio, while raising the price target from $23 to $25. This adjustment reflects a positive outlook on the company's future performance, indicating that analysts are optimistic about its potential for growth.

This positive sentiment is further supported by the consensus recommendation from brokerage firms, which currently stands at 1.8, indicating an "Outperform" status. This rating scale ranges from 1 to 5, with 1 signifying a Strong Buy and 5 denoting a Sell. The average brokerage recommendation underscores the overall bullish stance on Cabaletta Bio's prospects.